TargetElongin-B/Elongin-C [17-112]/von Hippel-Lindau disease tumor suppressor [55-213](Homo sapiens (Human))
Genentech
US Patent
Genentech
US Patent
Affinity DataIC50: 6.55E+4nMAssay Description:The binding of test compounds to the VHL Elongin B/C complex was measured using a fluorescence polarization tracer competition assay. The VHL/Elongin...More data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+5nMAssay Description:The VHL NanoBRET™ Target Engagement Assay analyzes the apparent affinity of test compounds for VHL in cells by competitive displacement of a VHL Nano...More data for this Ligand-Target Pair